CN105688160A - Application of traditional Chinese medicine composition in preparation of drug for treating solar dermatitis - Google Patents
Application of traditional Chinese medicine composition in preparation of drug for treating solar dermatitis Download PDFInfo
- Publication number
- CN105688160A CN105688160A CN201610155352.3A CN201610155352A CN105688160A CN 105688160 A CN105688160 A CN 105688160A CN 201610155352 A CN201610155352 A CN 201610155352A CN 105688160 A CN105688160 A CN 105688160A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 93
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 206010041303 Solar dermatitis Diseases 0.000 title claims abstract description 28
- 229940079593 drug Drugs 0.000 title claims abstract description 17
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940093265 berberine Drugs 0.000 claims abstract description 9
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims abstract description 9
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000499 gel Substances 0.000 claims description 21
- 241000628997 Flos Species 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 46
- 239000000126 substance Substances 0.000 abstract description 6
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 235000018142 Hedysarum alpinum var americanum Nutrition 0.000 abstract 1
- 240000006461 Hedysarum alpinum var. americanum Species 0.000 abstract 1
- 206010019851 Hepatotoxicity Diseases 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 241000234435 Lilium Species 0.000 abstract 1
- 241000208966 Polygala Species 0.000 abstract 1
- 244000234609 Portulaca oleracea Species 0.000 abstract 1
- 235000001855 Portulaca oleracea Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241000915604 Scutellaria barbata Species 0.000 abstract 1
- 241000219784 Sophora Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000007686 hepatotoxicity Effects 0.000 abstract 1
- 231100000304 hepatotoxicity Toxicity 0.000 abstract 1
- 235000008216 herbs Nutrition 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 208000002193 Pain Diseases 0.000 description 21
- 230000036407 pain Effects 0.000 description 19
- 210000003491 skin Anatomy 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical group OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 14
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 12
- 208000001848 dysentery Diseases 0.000 description 10
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 9
- 229960002916 adapalene Drugs 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- 206010014025 Ear swelling Diseases 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 8
- 231100000869 headache Toxicity 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 206010007247 Carbuncle Diseases 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 208000010668 atopic eczema Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 208000011580 syndromic disease Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 206010037660 Pyrexia Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 5
- 206010012434 Dermatitis allergic Diseases 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 206010040844 Skin exfoliation Diseases 0.000 description 5
- 201000008937 atopic dermatitis Diseases 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 4
- 208000031971 Yin Deficiency Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 208000035861 hematochezia Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 230000036269 ulceration Effects 0.000 description 4
- 235000019165 vitamin E Nutrition 0.000 description 4
- 229940046009 vitamin E Drugs 0.000 description 4
- 239000011709 vitamin E Substances 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010006002 Bone pain Diseases 0.000 description 3
- 206010010726 Conjunctival oedema Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 208000028990 Skin injury Diseases 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 229960003291 chlorphenamine Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000035618 desquamation Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001678 irradiating effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 201000009890 sinusitis Diseases 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 208000004371 toothache Diseases 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 2
- 208000004429 Bacillary Dysentery Diseases 0.000 description 2
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 2
- 208000015220 Febrile disease Diseases 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000035617 depilation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 201000005113 shigellosis Diseases 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- 210000004243 sweat Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- -1 ultraviolet Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- KUKRLSJNTMLPPK-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2(C)C=CC1C2(C)C KUKRLSJNTMLPPK-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 201000002045 Ancylostomiasis Diseases 0.000 description 1
- 208000033211 Ankylostomiasis Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- GLVKGYRREXOCIB-UHFFFAOYSA-N Bornylene Natural products CC1CCC(C(C)(C)C)C=C1 GLVKGYRREXOCIB-UHFFFAOYSA-N 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 241001550206 Colla Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010052369 Encephalitis lethargica Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017894 Gastroenteritis bacillus Diseases 0.000 description 1
- 206010061166 Gastroenteritis bacterial Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020376 Hookworm infection Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 241000304447 Sempervivum tectorum Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 244000046101 Sophora japonica Species 0.000 description 1
- 235000010586 Sophora japonica Nutrition 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001366 anti-paroxysmal effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002137 anti-vascular effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000021551 crystal sugar Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-N hydroperoxyl Chemical compound O[O] OUUQCZGPVNCOIJ-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicine, and particularly relates to application of a traditional Chinese medicine composition in preparation of a drug for treating solar dermatitis. For overcoming the defects that an existing chemical treatment drug for solar dermatitis is large in hepatotoxicity and poor in treatment effect, the traditional Chinese medicine composition is prepared from purslane herb, notopterygium root, sophora flower, radix scutellariae, prepared rhizome of rehmannia, lilies, honeysuckle flowers, dandelions, fructus lycii, barbed skullcap herbs, ligusticum wallichii, radix angelicae, berberine, radix paeoniae alba, rhizoma zingiberis, liquorice root, fructus citri and polygala root. The traditional Chinese medicine composition has a good effect of treating or preventing solar dermatitis, is low in side effect and has remarkable clinical popularization value.
Description
The application is the divisional application of the applicant Cui Xinming application for a patent for invention (denomination of invention is: a kind of Chinese medicine composition treating solar dermatitis and preparation method thereof, and application number is: 2014101131128, and the applying date is: on March 25th, 2014) proposed。
Technical field
The invention belongs to pharmaceutical technology field, relate to a kind of Chinese medicine composition purposes in preparation treatment solar dermatitis medicine。
Background technology
Allergy is the allergy of a kind of body。When anaphylactogen (such as chemical substance, ultraviolet, dust etc.) enter internal after, be combined with mastocyte or basophilic granulocyte, produce leukotriene, the allergenic factor such as prostaglandin, when body second time accepts this " anaphylactogen ", mastocyte starts deformation, produces allergic phenomena。Research shows, allergic dermatitis and free radical have direct relation。The essence of allergic dermatitis is to produce the Oxidative demage reaction of substantial amounts of radical pair mastocyte and basophil in body。So-called free radical, exactly when body carries out metabolism, can seize an electronics of oxygen, and so this oxygen atom reforms into free radical。Free radical is very unstable, it to be captured electronics in the molecule of bodily tissue cell again and match making itself, when, after the dynamic electronics of cellular elements, it also becomes free radical, again go grab cell membrane or or nucleus molecule in electronics, so also known as producing new free radical。As, superoxide anion radical, hydroxy radical, hydroperoxyl radical and methyl free radicals, etc.。Allergic dermatitis (allergicdermatitis) is the skin allergy owing to contact hypersensitivity antigen (such as hundreds of kinds such as chemical substance, ultraviolet, pollen, dust, foreign proteins) causes, the I allergic reaction type that it is mainly mediated by IgE。Skin occur red and swollen, itch, welt, the skin disorder such as decortication。Main shows as the dermoreactions such as dermatitis, eczema, urticaria。
Common allergic dermatitis mainly has: contact dermatitis, solar dermatitis, cosmetic dermatitis, steroid-dependent dermatitis etc.。At present, the Western medicine for the treatment of solar dermatitis is a lot, but most drug therapeutic effect is poor, and also treats into the shortcomings such as high, side effect is big, even affects patient health time serious。It addition, also have a lot of Chinese medicines treating solar dermatitis, but great majority have that therapeutic effect difference, cure rate be low and the shortcoming such as treatment cycle length。Namely the object of the invention is in that to provide a kind of effect comprehensively, the Chinese medicine composition of the treatment solar dermatitis that clinical effectiveness is good。
The traditional Chinese medical science is thought, solar dermatitis is that skin interspaces of skin and muscles being loose, skin exposure portion, after daylight excessive radiation, is invaded in summer-heat poison, and pathogenic heat are fought mutually with QI and blood and fallen ill owing to body natural endowment is not strong。Being mainly in spring and summer season, show as health exposure portion such as face, cervical region, the back of the hand etc. and difform erythema, pimple, welt or vesicle occur, companion's local pruritus, scorching hot twinge, severe patient can cause the General Symptomies such as heating, headache, Nausea and vomiting。Its characteristics of incidence is that after sun exposure, skin lesion substantially increases the weight of, and gargalesthesia aggravates, and after lucifuge, symptom alleviates。Treatment solar dermatitis is usually and currently mainly relies on Western medicine at present, and side effect is big, and dependency is strong, causes that dose is increasing, causes vicious cycle。
Making a general survey of the research direction of world's new drug, mainly research and develop single chemicals and preparation thereof, started to develop biotechnology and natural medicinal plants after the eighties before the eighties, drug research direction tends to multiformity。In conjunction with modern Chinese medicine theory of development, from improving curative effect of medication, reducing the angle of side effect, through Chinese medicine ingredients carries out the preparation that screening is extracted and/or compatibility prepares, its side effect is little, and safety is high, has the advantage that chemical synthetic drug can not be compared。
Summary of the invention
In prior art, chemicals is cured the symptoms, not the disease, and easily damage is gastrointestinal tract mucous, and poisonous side effect of medicine is big, and it is fixed that Chinese medicine then exists uncertain therapeutic efficacy, lacks relative medicine preparation。In order to overcome existing solar dermatitis chemotherapeutic agent toxic and side effects big, it is not enough that solar dermatitis therapeutic effect is difficult to lasting prior art, the invention provides a kind of Chinese medicine composition treating solar dermatitis, this Chinese medicine composition good effect, side effect is little, it is mainly prepared by following raw material: Herba Portulacae 10-50 part, Rhizoma Et Radix Notopterygii 10-20 part, Flos Sophorae 5-20 part, Radix Scutellariae 5-15 part, Radix Rehmanniae Preparata 5-10 part, Bulbus Lilii 5-15 part, Flos Lonicerae 5-15 part, Herba Taraxaci 1-10 part, Fructus Lycii 5-15 part, Herba Scutellariae Barbatae 9-15 part, Rhizoma Chuanxiong 9-15 part, Radix Angelicae Dahuricae 5-15 part, berberine 0.2-9 part, Radix Paeoniae Alba 5.5-15 part, Rhizoma Zingiberis 6-9 part, Radix Glycyrrhizae 10-15 part。
Herba portulacae has heat-clearing and toxic substances removing, damp eliminating leukorrhagia stopping effect, it is adaptable to damp invasion of lower energizer, leucorrhea with yellow discharge, sticky taste are smelly, oliguria with yellow urine, thirsty bitter taste, red tongue with yellow fur, rolling pulse person, also can be used for diarrhea due to damp-heat, dysentery etc.。Energy insect-expelling function, it is adaptable to infantile ancylostomiasis。These product have heat-clearing and toxic substances removing, antidiarrheal dysentery, except intestinal dirt, QI invigorating qi-restoratives effect, it is adaptable to treatment chronic dysentery。
Rhizoma Et Radix Notopterygii is conventional Chinese medicine。Medicinal history is long, first appeared in Shennong's Herbal, is listed under Radix Angelicae Pubescentis item。Rhizoma Et Radix Notopterygii bitter in the mouth, pungent, warm in nature。There is scattered exterior cold curing rheumatism, the effect in profit joint。Control affection of exogenous wind-cold, have a headache lossless, anemofrigid-damp arthralgia, stiffness of the nape muscular contracture, joint are ached, edema due to wind pathogen edema, the swollen sore of pain etc.。Modern analysis shows, Rhizoma Et Radix Notopterygii mainly contains bornene, twists rubber alkene, talks about the composition such as product enol and acetic acid Radix Gentianae brain vinegar。It is clinically used for impotence and seminal emission, enuresis frequent micturition, chills and pain of the waist and kness, suffers from a deficiency of the kidney and breathe heavily, Diarrhoea；External curing vitiligo, alopecia areata。Induce sweat the diseases such as cold expelling, expelling wind and dampness, pain relieving。Modern pharmacology research Rhizoma Et Radix Notopterygii has significant antipyretic and anti-inflammatory and paroxysmal pain effect。
Flos Sophorae is again Chinese scholartree stamen, effect of Flos Sophorae: cooling blood for hemostasis, liver heat removing and eyesight improving, Flos Sophorae effect: control discharging fresh blood stool, hemorrhoid hematochezia, hematuria stranguria with blood, liver-heat headache, conjunctival congestion and swelling pain, Flos Sophorae medication is avoided: Deficiency and coldness of spleen and stomach person is careful takes Flos Sophorae, Flos Sophorae can (drugs) to be decocted and taken as a drink, Flos Sophorae also can be equal to use with Spica Prunellae, Flos Chrysanthemi, Radix Scutellariae, to increase the effect of purging liver-fire improving eyesight。Clinic cures mainly: discharging fresh blood stool；Hemorrhoid hematochezia；Dysentery；Hematuria；Stranguria with blood；Metrorrhagia；Spit blood；Epistaxis；Liver-heat is had a headache；Conjunctival congestion and swelling pain；Carbuncle skin infection。
Radix Scutellariae another name Radix Scutellariae, tsuchikane tea root。For labiate Radix Scutellariae (ScutellariabaicalensisGeorgi), it is used as medicine with root。Having heat clearing and damp drying, removing heat from blood is antiabortive, detoxicating functions。Cure mainly the diseases such as epidemic febrile disease, upper respiratory tract infection, cough due to lung-heat, damp and hot jaundice, pneumonia, dysentery, hemoptysis, conjunctival congestion, frequent fetal movement, hypertension, carbuncle furuncle。The clinical practice of Radix Scutellariae is antibacterial not worse than Rhizoma Chuanxiong, and does not develop immunity to drugs。
Radix Rehmanniae Preparata is the tuber of scrophulariaceae rehmannia glutinosa plant, has another name called Radix Rehmanniae Preparata or throws oneself on the ground, and the processed process of preparing Chinese medicine forms。Radix Rehmanniae Preparata is a kind of first-class Chinese crude drug, has YIN nourishing effect of enriching blood, can be used for blood deficiency and yellow complexion, dizziness, palpitation and insomnia, menoxenia, the diseases such as metrorrhagia, also can be used for hectic fever hectic fever due to YIN-deficiency, the night sweat of deficiency of kidney yin, pass out semen, the disease such as quench one's thirst, and are one of deficiency syndrome class nonprescription drugs medicine LIUWEI DIHUANG WAN main components。Radix Rehmanniae Preparata is first appeared in Shennong's Herbal, and Clinical practice has fresh, raw, ripe three kinds。All there is the merit of YIN nourishing and the production of body fluid promoting, and control all cards of Yin and fluid deficiency。Radix Rehmanniae sweetness and bitterness Great Cold, though the power of YIN nourishing is weak, but it is longer than clearing away heat and cooling blood, pathogenic fire purging relieving restlessness, it is used for heat in blood heresy and contains, syndrome of yin deficiency and depletion of fluid；The power of raw (do) Radix Rehmanniae sweet cold matter profit removing heat from blood is slightly inferior but is longer than the moon of the kidney that nourishes heart, Gu Xuereyin injure fever due to yin deficiency person suitable it；Radix Rehmanniae Preparata is sweet in flavor and warm in property, enters Liver and kidney and the special nourishing the blood and yin of merit, life essence-filling, marrow-benefitting, all kidney-YIN being deficient, marrow virtual loss person, all can use it。Radix Rehmanniae Preparata is used for insufficiency of kidney-YANG, decline of the fire from the gate of life, aversion to cold and cold limbs, impotence and seminal emission, and urine loses drop, or the anorexia and loose stool of YANG failing to warm spleen-YANG, many product adapteds with the warming YANG such as Radix Aconiti Lateralis Preparata, Cortex Cinnamomi, this namely so-called " being apt to YANG invigorating person, must in treating YANG within YIN " meaning。With controlling carbuncle of yin nature cold coagulation, this product often and the adapted such as Colla cornus cervi, Cortex Cinnamomi, Herba Ephedrae with channel warming and blood nourishing, cold expelling is promoted blood circulation。
The traditional Chinese medical science thinks that Bulbus Lilii has the effect of nourishing the lung to arrest cough, clearing away heart-fire for tranquillization, and especially fresh Bulbus Lilii is more sweet delicious。Bulbus Lilii is particularly suitable for supporting lung, the people of nourishing the stomach eats, the such as patient of chronic cough, pulmonary tuberculosis, aphtha of the mouth and tongue, xerostomia, halitosis。Bulbus Lilii not only has good nutritious tonifying effect, and of great advantage for patients such as deficient syndrome after being ill, tuberculosis, neurosiss, and various cancers are had good curative effect。In the prevention and treatment of tumor, Bulbus Lilii is used for treatment pulmonary carcinoma, nasopharyngeal carcinoma, skin carcinoma etc.。During the symptoms such as body void weak, xerostomia, vexed, the dry cough expectorant occurred after above-mentioned cancer is carried out radiotherapy, cook congee together with Semen oryzae sativae with fresh Bulbus Lilii, call in after appropriate crystal sugar or Mel edible again, to health invigorating, anticancer growth, alleviate the reaction of radiotherapy, there is good effect。For another example, fresh Bulbus Lilii and white sugar being smash deposited affected part in right amount altogether, skin carcinoma ulceration is hemorrhage, infiltration person also has certain therapeutical effect。
Flos Lonicerae is cold in nature, sweet in the mouth, enters lung, the heart, stomach warp, has heat-clearing and toxic substances removing, antiinflammatory, qi-restoratives treat effect of wind, cure mainly disease under distension, epidemic febrile disease heating, the disease such as pyretic toxicity carbuncle and ulcer and tumor。It all has certain curative effect for diseases such as dizzy dizzy, xerostomia is made yearningly, hyperhidrosis unhappiness, gastroenteritis, bacillary dysentery, measles, pneumonia, encephalitis b, epidemic encephalitis, acute mastitis, septicemia, appendicitis, skin infection, carbuncle furuncle, erysipelas, parotitis, suppurative tonsillitiss。Flos Lonicerae tea has the weight losing function of uniqueness simultaneously, moreover it is possible to the pathogen suppressing with killing bottleneck throat, and old man and child are had infection effect。So, often take Flos Lonicerae and soak or decoct is conducive to wind-fire conjunctival congestion, laryngopharynx swelling and pain, obesity, the treatment of liver-heat disease regulating liver-QI pattern of fever hypertension and rehabilitation。
Herba Taraxaci has the effect of heat-clearing and toxic substances removing, can be used for heat toxin syndrome, especially kind removing heat from the liver, treats liver-heat conjunctival congestion and swelling pain and multi-infection, purulent disease；The treatment pyretic toxicity heap soil or fertilizer over and around the roots of eliminating carbuncle eliminating stagnation is tied in the carbuncle sore tumefacting virus caused by muscle, hyperpyrexia。Acute mastitis is had good effect, energy detoxicating and resolving stagnation of pathogens lactogenesis, oral administration or external application, often joins the equivalent use of Flos Lonicerae。Additionally also can join Radix Et Rhizoma Rhei, Cortex Moutan treatment acute appendicitis。
Fructus Lycii (formal name used at school: Lyciumchinense) is the multi-branched shrub plant of Solanaceae Lycium, and high 0.5-1 rice, up to more than 2 meters during cultivation。All there is distribution both at home and abroad。Fructus Lycii whole body is precious, and bright Li Shizhen (1518-1593 A.D.) Compendium of Material Medica is recorded: " spring adopts Folium Lycii, name sky essence grass；Summer picks flowers, name Sempervivum tectorum；Qiu Caizi, name Fructus Lycii；Dong Caigen, name Cortex Lycii "。Fructus Lycii tender leaf also known as Fructus Lycii head, edible or make Fructus Lycii tea。Modern study, Fructus Lycii has reduction blood glucose, lipotropy, and can antiatherogenic effect。
Herba Scutellariae Barbatae is the dry aerial parts of labiate Herba Scutellariae Barbatae, tool heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, the function such as anticancer。Primarily now with Herba Hedyotidis Diffusae with the use of, be used for extending existence life-span of patients with bowel cancer。Meanwhile, Herba Scutellariae Barbatae heat-clearing and toxic substances removing, dissipating blood stasis, hemostasis, analgesic therapy, cancerous protuberance, traumatic injury knife injury, venom etc.。
The pungent temperature of Rhizoma Chuanxiong is fragrant dry, walks and does not keep, can go scattered, up up to top, mountain peak；Enter again blood system, descending up to the sea of blood。Blood circulation promoting and blood stasis dispelling effect is extensive, the suitable various disease of stagnation of blood stasis；Wind-expelling pain-stopping, effectiveness is excellent, can control the diseases such as wind syndrome of head headache, rheumatic arthralgia。It is the gas medicine in blood that former times people calls Rhizoma Chuanxiong, the function such as its residence of dangerous speech is pungent to be dissipated, resolving depression, sensible, pain relieving。The pungent temperature rise of this product dissipates, and all hyperactivity of YANG due to deficiency of YIN and excessive rising of liver-YANG person should not apply；Menorrhagia, anemia of pregnant woman also avoid use。
The Radix Angelicae Dahuricae, warm in nature, acrid in the mouth is micro-sweet, has expelling wind and removing dampness；Logical surreptitiously pain relieving；Effect of detumescence and apocenosis。Main headache due to common cold；Supraorbital bone pain；Toothache；Nasal obstruction；Nasal sinusitis；Domination of damp pathogen chronic diarrhea；Women leucorrhea；Ulcer sores；Venom。Being clinically used for headache due to common cold, supraorbital bone pain, nasal obstruction, nasal sinusitis, toothache, leucorrhea, skin infection swells and ache。Can also be used for the cold expelling that induces sweat, wind-expelling pain-stopping, clearing the nasal passage, dampness leukorrhagia stopping, detumescence and apocenosis。Controlling headache, supraorbital bone pain, toothache, nasal sinusitis, cold-damp is suffered from abdominal pain, hemorrhoidal hamorrhage anal fistula, leucorrhea with red and white discharge, ulcer sores, skin pruritus due to dryness, scabies。Rhizoma Atractylodis have drying damp and strengthening spleen, expelling wind and cold, effect of improving eyesight, and for dampness taste, distension and fullness in the abdomen, cold-damp leucorrhea, damp-warm diseases and damp invasion of lower energizer, foot swelling and pain in knee, flaccidity are soft unable。Control dampness taste, and see the thick disease such as turbid of distension and fullness in the abdomen, inappetence, fatigue and weakness, white and greasy fur, often apply with the compatibility such as Cortex Magnoliae Officinalis, Pericarpium Citri Reticulatae。
Berberine is used for treating diarrhoea as nonprescription drugs in clinic always, but modern pharmacology research confirms that berberine has significant heart failure resistance, arrhythmia, reduction cholesterol, anti-vascular smooth muscle cell proliferation processed, improves the effects such as insulin resistant, antiplatelet, antiinflammatory, thus have extensive, important application prospect by being likely in cardiovascular system and nervous system disease, it is increasingly subject to pay attention to。Berberine is a kind of important alkaloid, is China's application Chinese medicine for a long time。Can extract from the plants such as Rhizoma Coptidis, Cortex Phellodendri, Radix Berberidis。It has significant bacteriostasis。Conventional berberine hydrochloride is again berberine hydrochloride。Berberine can to resisting pathogenic microbes, various bacteria such as dysentery bacterium, tubercule bacillus, streptococcus pneumoniae, Bacillus typhi and diphtheria corynebacterium etc. there is inhibitory action, wherein that dysentery bacterium effect is the strongest, it is commonly used to the treatment digestive tract disease such as bacterial gastroenteritis, dysentery。Clinic is mainly used in treatment bacillary dysentery and gastroenteritis, and it is without Drug resistance and side effect。
The Radix Paeoniae Alba is traditional parts of generic medicinal plants that China is famous, and applicating history is long, and Radix Paeoniae begins to be loaded in Eastern Han Dynasty's Shennong's Herbal, is classified as middle product, and note has " main pathogen, the Radix Paeoniae Alba is suffered from abdominal pain, and except arthralgia due to stagnation of blood, broken heavily fortified point is long-pending, cold and heat hernia abdominal mass, pain relieving, diuresis, QI invigorating "。Nourishing blood to suppress the hyperactive liver, pain relieving in slow, yin fluid astringing receives antiperspirant。Controlling the chest and abdomen pain over the hypochondriac region, dysentery is suffered from abdominal pain, spontaneous sweating, fever due to yin deficiency, menoxenia, and inferior disease is with in metrorrhagia。Modern pharmacology research display, paeoniflorin is to Cavia porcellus, the intestine in vitro of rat and moves at stomach, and rat uterus smooth muscle all shows suppression, and can contraction caused by antagonism oxytocin；With acetic acid injection in mouse peritoneal, using writhing response as the index of pain, paeoniflorin has significant analgesic effect；The convulsions caused by extractum energy antagonism strychnine of Radix Paeoniae；Dysentery bacterium is in vitro had bacteriostasis by Radix Paeoniae Alba decoct, and some pathogenic fungus is also had inhibitory action by preserved material。White mice normal body temperature is had cooling effect by paeoniflorin, and the mice of artificial fever is also had refrigeration function。Rat Experimental metapedes sole of the foot edema there is antiinflammatory action；The rat platelet aggregation of adenosine diphosphate (ADP) induction in vitro or is had inhibitory action during intravenous injection by paeoniflorin；The digestive tract in rats ulcer brought out owing to anxiety irritates is had obvious inhibitory action by paeoniflorin。
Rhizoma Zingiberis Shennong's Herbal is classified as middle product, and Rhizoma Zingiberis Recens " Mingyi Bielu " is classified as middle product。TAO Hong-Jing is called: " all making Rhizoma Zingiberis method: water logging three days, peeling is put in flowing water six, and then more random peeling is dried, put in Porcelain Jar and make three, be into。" Li Shizhen (1518-1593 A.D.) meaning Rhizoma Zingiberis makes it with female Rhizoma Zingiberis Recens, with fair and clear solid person for good, all it is used as medicine and Yi Pao use。Rhizoma Zingiberis is used for warming up spleen sun, partially controls spleen-cold syndrome stomachache and has loose bowels。Promoting blood circulation by recuperating depleted YANG again, warming the lung to resolve fluid-retention, with controlling yang depletion syndrome, four cold of the limbs are inverse, faint pulse being about to disappear, and cold fluid-retention cough with asthma, and the cold physique back of the body is cold, the clear rare disease such as grade of abundant expectoration。
Chinese medicine composition of the present invention to remove long-pending numbness, dispersing wind and cold, wind-damp dispelling, bone and muscle strengthening for main standard, has significant antiinflammatory, analgesia and activating blood circulation to dissipate blood stasis effect after Chinese medicine composition of the present invention combination on Chinese medicinal components selects。The parts by weight of above-mentioned all taste Chinese medicine have been carried out preferably by the present invention, it is preferred that condition is the medicine enhancing to solar dermatitis therapeutic effect after Chinese medicine and western medicine compatibility uses。As a preferred embodiment of the present invention, Chinese medicine composition of the present invention is mainly prepared by the raw material of following weight portion: Herba Portulacae 30 parts, Rhizoma Et Radix Notopterygii 15 parts, 15 parts of Flos Sophorae, Radix Scutellariae 10 parts, 8 parts of Radix Rehmanniae Preparata, Bulbus Lilii 10 parts, Flos Lonicerae 10 parts, Herba Taraxaci 6 parts, Fructus Lycii 10 parts, Herba Scutellariae Barbatae 12 parts, Rhizoma Chuanxiong 12 parts, the Radix Angelicae Dahuricae 10 parts, berberine 5.5 parts, the Radix Paeoniae Alba 10 parts, Rhizoma Zingiberis 8 parts, 12 parts of Radix Glycyrrhizae。
Preferably, the Chinese medicine composition of the present invention also contains Fructus Citri 5 parts, Radix Polygalae 9 parts further。Fructus Citri has another name called citron, for Rutaceae citrus plant, and Fructus Citri acrid in the mouth, micro-hardship, acid, warm in nature；Return liver, lung, spleen channel；Gas perfume (or spice) row dissipates, and can rise and can drop；Having depressed liver-energy dispersing and QI regulating, the chest stuffiness relieving reduces phlegm, dehumidifying and in effect, cure mainly distending pain in the chest and hypochondrium, cough with copious phlegm, gastral cavity abdomen painful abdominal mass pain, dyspepsia vomiting, edema beriberi。Radix Polygalae is conventional Chinese medicine, it is recorded in Shennong's Herbal the earliest, is classified as top grade, and be considered to support life key medicine, warm in nature, function that is bitter in the mouth, pungent, that there is Fructus Alpiniae Oxyphyllae of calming the nerves, eliminate the phlegm, subside a swelling, the insomnia and dreamful sleep caused for disarmony between the heart and kidney, forgetful palpitation with fear, staring spells, expectoration is not well, sore swollen toxin, breast swell and pain。
In order to better express the Chinese medicine composition of the present invention, the present invention can be prepared as dosage form conventional clinically。Such as, the preparation such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule。Preferably, Chinese medicine composition of the present invention conventionally preparation technology prepares into powder, gel, tablet or capsule。
The preparation method that present invention also offers a kind of Chinese medicine composition described above, comprise following step: take the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, the alcoholic solution that volumetric concentration is 40%-95% is added according to 4-9 times of coarse powder gross weight, reflux, extract, three times, return time is 2-5h, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying；Pulverized the berberine adding recipe quantity after making dried cream powder and Herba Taraxaci can be obtained Chinese medicine composition of the present invention。Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically in this preparation method, such as tablet, capsule etc.。
The present invention is also claimed above-mentioned Chinese medicine composition purposes in preparation treatment solar dermatitis medicine。Pharmaceutical composition of the present invention is when treating solar dermatitis, it is shown that significant anti-inflammatory and antalgic, activating blood circulation to dissipate blood stasis activity。Test examples 19 of the present invention shows, compare with model group, low middle high three the dosage groups of Chinese medicine composition of the present invention all can significantly reduce the ear swelling value (P < 0.01) of dimethylbenzene induced mice, show that Chinese medicine composition of the present invention has the effect of the mice ear significantly inhibiting dimethylbenzene induction, and the reducing effect of ear swelling is existed significant dose-effect relationship by it。Under same experiment condition, positive control drug chlorphenamine group is significantly reduced ear swelling value (P < 0.05), but its antiphlogistic effects is substantially not as good as Chinese medicine composition of the present invention。
In a word, pharmaceutical composition of the present invention, in treatment solar dermatitis, compared with prior art has the advantage that
1) compared with positive control drug, pharmaceutical composition Chinese medicine composition of the present invention is not only more notable at antiinflammatory and ease pain, and in activating blood circulation to dissipate blood stasis, also it is significantly better than positive drug, this shows that the present composition has significant synergism in solar dermatitis is treated, the symptom of solar dermatitis can not only be significantly improved, the development of solar dermatitis can also be delayed, contribute to the recovery process of solar dermatitis patient；
2) compared with the chemotherapeutic agent of Current therapeutic solar dermatitis, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, untoward reaction and side effect significantly reduce, particularly it does not produce any destruction for intestinal mucosa, and Chinese medicine composition effect of the present invention is comprehensive, medication effect more preferably, significantly improves the compliance of solar dermatitis patient, and improves the quality of life of patient。
Detailed description of the invention
Further describing the present invention below by way of specific embodiment, the present invention is not limited only to following example。Within the scope of the invention or without departing from present disclosure, spirit and scope, change, combination or the replacement that the present invention is carried out, will be apparent to the person skilled in the art, and be included within the scope of the present invention。
Part I Chinese medicinal composition preparation of the present invention, preparation and using method thereof
Embodiment 1-6 Chinese medicine composition composition powders
Table 1 Chinese medicine composition composition powders prescription of the present invention
Embodiment 1 preparation method: take each medical material in compositions, conventionally technique grinds to form powdery, crosses 100 mesh sieves, and little fire drying is standby, obtains powder。During use, directly take after mixing it with water with after water dissolution。Embodiment 2-6 preparation method is with embodiment 1。
Embodiment 7-12 Chinese medicine composition gelata
Table 2 Chinese medicine composition gelata prescription of the present invention
Embodiment 7 preparation method: take each medical material, conventionally decocting for Chinese herbal medicine technological operation in prescription, adds appropriate glyceryl monostearate and dimethicone and get final product after filtering medicinal residues。When this gel (or claiming decoction) is treated for solar dermatitis, every day smears 2-3 time。Embodiment 8-12 preparation method and using method are with embodiment 7。
Embodiment 13-18 Chinese medicine composition tablet/capsule of the present invention
Table 3 Chinese medicine composition tablet of the present invention/capsule prescription
Embodiment 13 preparation technology: each traditional Chinese medicine powder taking recipe quantity is broken into coarse powder, adding volumetric concentration according to 5 times of coarse powder gross weight is the alcoholic solution of 80%, reflux, extract, three times, the each 3h of return time, filters, filtrate recycling ethanol, cold filtration, washes with water, namely obtains Chinese medical concrete after drying；By Chinese medical concrete drying, pulverize and make dried cream powder, add customary adjuvant components utilising prior art and prepare into tablet or capsule。
Embodiment 14-18 preparation technology is with embodiment 13。
Part II Chinese medicine composition pharmacodynamic study of the present invention
Embodiment 19 Chinese medicine composition xylol of the present invention causes the impact of mice ear
Take healthy ICR mice 72, ♀ ♂ half and half, divide 6 groups, 12/group, i.e. model group, hydrocortisone (Hainan company limited of SANYE pharmaceutical factory, lower same), chlorphenamine group (Haikou Kangliyuan Pharmaceutical Co., Ltd), Chinese medicine composition of the present invention (preparing by Chinese medicine composition prescription described in embodiment 1 and preparation technology) low dose group, middle dosage group and high dose group。Every ig is administered 1 time/d；Administration 14d, 60min after last medicine, mouse right ear uniform application dimethylbenzene 0.03mL/ only causes swollen, cuts ears and beat auricle and weigh after 2h, calculates ear swelling value (mg)。Swelling value=auris dextra weight-left ear weight。
Result shows, compare with model group, low middle high three the dosage groups of Chinese medicine composition of the present invention all can significantly reduce the ear swelling value (P < 0.01) of dimethylbenzene induced mice, show that Chinese medicine composition of the present invention has the effect of the mice ear significantly inhibiting dimethylbenzene induction, and the reducing effect of ear swelling is existed significant dose-effect relationship by it。Under same experiment condition, positive control drug chlorphenamine group is significantly reduced ear swelling value (P < 0.05), but its antiphlogistic effects is substantially not as good as Chinese medicine composition of the present invention。
The impact of table 4 Chinese medicine composition of the present invention xylol induced mice ear swelling ()
Note: compare with model group, * P < 0.05, * * P < 0.01。
Skin photoage that ultraviolet is caused by embodiment 20 Chinese medicine composition of the present invention and the impact of hydroderma
20.1 the protective effect of the skin photoage that ultraviolet is caused by Chinese medicine composition of the present invention
Mice being randomly divided into 6 groups: model group gives gel-type vehicle, the present composition gel of embodiment 7 preparation is divided into high and low dose group, and positive controls 1 gives vitamin E；Positive controls 2 gives chlorphenamine；Positive controls 3 gives adapalene gel。Mouse back depilation before experiment, exposed area 4cm × 3cm, each group is preventative smears 3d。Mice is placed under uviol lamp (40WUVA tube 5, UVB fluorescent tube 2), and distance skin 35cm place is irradiated, and during irradiation, paper using is pulled and covered animal head。The initial illumination time is 4h/d, progressively increases to 12h/d, Continuous irradiation 4 weeks, perusal record the situation of change of skin in the process irradiated。
20.2 the impact of the hydroderma that ultraviolet is caused by Chinese medicine composition of the present invention
Mice being randomly divided into 6 groups: model group gives gel-type vehicle, the present composition gel of embodiment 1 preparation is divided into high and low dose group, positive controls 1 to give prednisolone acetate ointment (Tianjin Pharmaceutical Group Corp., Ltd)；Positive controls 2 gives chlorphenamine；Positive controls 3 gives adapalene gel。Mouse back depilation, exposed area 4cm × 3cm before experiment；Each group is preventative smears 7d。Being horizontally fixed on brandreth by mice, (40WUVA fluorescent tube 4, UVB fluorescent tube 16 vertical dimension 10cm, Continuous irradiation 6h, during irradiation, paper using plate covers animal head with uviol lamp。40h after irradiation, disconnected ridge puts to death mice, take two ears (d=0.7cm) and back (d=2cm) irradiated circular skin graft respectively, accurately weigh ear weight, tare weight and body weight, calculate ear index and skin index: { ear (skin) index=ear (skin) weight (mg)/body weight (g) × 100}。
20.2.1 result
20.2.1.1 perusal
After irradiating 4d, there is serious big red and swollen, desquamation in the illuminated skin of model group mice；With present composition gel group, chlorphenamine group, adapalene gel group skin injury situation relatively model group gently, desquamation phenomenon is less for vitamin E。Wherein present composition gel group is red and swollen, desquamation phenomenon is lighter than chlorphenamine group and adapalene gel group。
Irradiating after 15d, there is large area lamellar erythema, festers, forms a scab in the illuminated skin of model group mice, local skin thickens；Vitamin E, present composition gel group and chlorphenamine group skin injury situation relatively model group are light, and erythema is few, ulceration is lighter。Wherein present composition gel group effect is better than chlorphenamine group and adapalene gel group。
Irradiating after 24d, the illuminated skin of model group mice presents lamellar erythema, festers, vesicle, thicken, tarnish and elasticity, aging substantially；Gently, erythema is few, ulceration is light, vesicle quantity is few, pachyderma is inconspicuous for vitamin E, present composition gel group and chlorphenamine group, adapalene gel group skin injury situation relatively model group。Wherein present composition gel group relatively chlorphenamine group, adapalene gel group ulceration are slight, and vesicle quantity is few, and vesicle is little。
20.2.1.2 the impact of hydroderma
As can be seen from Table 1: present composition gel group can reduce mouse ear index, skin index, difference is very significant (P < 0.01), and its effect is better than chlorphenamine group。
The table 1 impact on mouse ear index, skin index
Compare * * P < 0.01, * P < 0.05 with model group, compare △ △ P < 0.01, △ P < 0.05 with chlorphenamine group；
Compare ☆ ☆ P < 0.01, ☆ P < 0.05 with adapalene gel group, compare ▲ ▲ P < 0.01, ▲ P < 0.05 with prednisolone acetate group。
It is shown that the therapeutic effect of present composition preparation is better than chlorphenamine and adapalene gel。
Claims (3)
1. a Chinese medicine composition treats the purposes in solar dermatitis medicine in preparation, it is characterised in that described Chinese medicine composition is prepared by the raw material of following weight portion: Herba Portulacae 30 parts, Rhizoma Et Radix Notopterygii 15 parts, 15 parts of Flos Sophorae, Radix Scutellariae 10 parts, 8 parts of Radix Rehmanniae Preparata, Bulbus Lilii 10 parts, Flos Lonicerae 10 parts, Herba Taraxaci 6 parts, Fructus Lycii 10 parts, Herba Scutellariae Barbatae 12 parts, Rhizoma Chuanxiong 12 parts, the Radix Angelicae Dahuricae 10 parts, berberine 5.5 parts, the Radix Paeoniae Alba 10 parts, Rhizoma Zingiberis 8 parts, 12 parts of Radix Glycyrrhizae, Fructus Citri 5 parts and Radix Polygalae 9 parts。
2. purposes as claimed in claim 1, it is characterised in that: described Chinese medicine composition is powder, gel, tablet or capsule。
3. purposes as claimed in claim 1, it is characterized in that: described Chinese medicine composition is prepared by the method for being made by: take the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, adding the alcoholic solution that volumetric concentration is 40%-95%, reflux, extract, three times according to 4-9 times of coarse powder gross weight, return time is 2-5h, filter, filtrate recycling ethanol, cold filtration, wash with water, namely obtain Chinese medical concrete after drying, the basis of above Chinese medical concrete can be prepared by described Chinese medicine composition。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610155352.3A CN105688160A (en) | 2014-03-25 | 2014-03-25 | Application of traditional Chinese medicine composition in preparation of drug for treating solar dermatitis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410113112.8A CN103893722B (en) | 2014-03-25 | 2014-03-25 | A traditional Chinese medicine composition for treating solar dermatitis and its preparation method |
| CN201610155352.3A CN105688160A (en) | 2014-03-25 | 2014-03-25 | Application of traditional Chinese medicine composition in preparation of drug for treating solar dermatitis |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410113112.8A Division CN103893722B (en) | 2014-03-25 | 2014-03-25 | A traditional Chinese medicine composition for treating solar dermatitis and its preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105688160A true CN105688160A (en) | 2016-06-22 |
Family
ID=50985506
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610155331.1A Withdrawn CN105688159A (en) | 2014-03-25 | 2014-03-25 | Method for preparing traditional Chinese medicine composition for treating solar dermatitis |
| CN201610155352.3A Withdrawn CN105688160A (en) | 2014-03-25 | 2014-03-25 | Application of traditional Chinese medicine composition in preparation of drug for treating solar dermatitis |
| CN201410113112.8A Active CN103893722B (en) | 2014-03-25 | 2014-03-25 | A traditional Chinese medicine composition for treating solar dermatitis and its preparation method |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610155331.1A Withdrawn CN105688159A (en) | 2014-03-25 | 2014-03-25 | Method for preparing traditional Chinese medicine composition for treating solar dermatitis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410113112.8A Active CN103893722B (en) | 2014-03-25 | 2014-03-25 | A traditional Chinese medicine composition for treating solar dermatitis and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN105688159A (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104740566B (en) * | 2015-03-26 | 2018-05-29 | 鼎旺生物科技有限公司 | A preparation for reducing skin inflammation, preparation method and application thereof |
| CN104984046B (en) * | 2015-06-25 | 2019-02-26 | 湖北中医药大学 | A traditional Chinese medicine external preparation for treating allergic skin diseases and preparation method thereof |
| CN105168532A (en) * | 2015-07-23 | 2015-12-23 | 青岛蓝盛洋医药生物科技有限责任公司 | Pharmaceutical composition for treating solar dermatitis and preparation method of pharmaceutical composition |
| CN105213570A (en) * | 2015-09-29 | 2016-01-06 | 罗奕珺 | A pharmaceutical composition for treating solar dermatitis and its preparation method |
| CN105878560A (en) * | 2015-10-10 | 2016-08-24 | 烟台市蓝洋之草医药生物科技有限公司 | Method for preparing medical composition capable of treating solar dermatitis |
| CN105311427A (en) * | 2015-11-18 | 2016-02-10 | 暨南大学 | Pharmaceutical composition containing folium artemisiae argyi for treating solar dermatitis |
| CN105327032A (en) * | 2015-11-26 | 2016-02-17 | 王辉 | Traditional Chinese medicine composition for treating solar dermatitis, preparation method and use method thereof |
| CN108815303A (en) * | 2018-09-03 | 2018-11-16 | 文勇 | A kind of composition and preparation method thereof for treating prostatitis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488791B (en) * | 2011-12-11 | 2013-11-20 | 王英婷 | Chinese traditional medicine granule for eczema and dermatitis |
-
2014
- 2014-03-25 CN CN201610155331.1A patent/CN105688159A/en not_active Withdrawn
- 2014-03-25 CN CN201610155352.3A patent/CN105688160A/en not_active Withdrawn
- 2014-03-25 CN CN201410113112.8A patent/CN103893722B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103893722B (en) | 2016-06-01 |
| CN103893722A (en) | 2014-07-02 |
| CN105688159A (en) | 2016-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105688160A (en) | Application of traditional Chinese medicine composition in preparation of drug for treating solar dermatitis | |
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN102784363A (en) | Traditional Chinese medicine composition for treating pancreatic cancer and preparation method thereof | |
| CN102078569B (en) | Traditional Chinese medicine preparation for treating liver cancer and preparation method thereof | |
| CN102526498A (en) | Chinese medicine for eliminating toxic and side effects after nasopharyngeal carcinoma radiotherapy and preparation method and administration way thereof | |
| CN104338031A (en) | Leukocyte-increasing traditional Chinese medicine decoction piece combined preparation as well as preparation method and combined package thereof | |
| CN105435197A (en) | Pharmaceutical composition for treating chronic lymphocytic thyroiditis and preparation method thereof | |
| CN103432466B (en) | Female pelvic inflammatory disease treatment traditional Chinese medicine composition and preparation method thereof | |
| CN104352866A (en) | Traditional Chinese medicine preparation for treating fire-toxin fluid-impairment type burns and preparation method thereof | |
| CN105521332A (en) | Traditional Chinese medicinal composition for treating anal fissure, and preparation method and application thereof | |
| CN104840773A (en) | Traditional Chinese medicine composition for treating vertebral artery type cervical spondylopathy and method for preparing same | |
| CN104906502A (en) | Pharmaceutical composition for treatment of chicken damaged by heat and preparation method thereof | |
| CN105617268A (en) | Medicine for treating scale keratinization type beriberi | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN105169278A (en) | Dandelion oral liquid capable of protecting liver and benefiting gallbladder and preparation method thereof | |
| CN103417836B (en) | Chinese medicine composition for the treatment of tumor and preparation method thereof | |
| CN103381215A (en) | Traditional Chinese medicine composite for curing cholecystitis and cholelithiasis and preparation method thereof | |
| CN104707003B (en) | The Chinese medicinal capsule for the treatment of hypertension, hyperlipidemia | |
| CN105169277A (en) | Fructus gardeniae oral liquid capable of protecting liver and benefiting gallbladder and preparation method thereof | |
| CN104587376A (en) | Drug for treating qi stagnation and blood stasis-type thoracic obstruction and preparation method of drug oral liquid | |
| CN105267895A (en) | Medicine for treating bovine postpartum blood stasis type placenta retension and preparing method thereof | |
| CN104922595A (en) | Traditional Chinese medicinal preparation for herpes zoster and preparation method thereof | |
| CN105169275A (en) | Rheum officinale oral liquid capable of protecting liver and benefiting gallbladder and preparation method thereof | |
| CN104606537A (en) | Qi-reinforcing and blood-nourishing medicated diet for improving chemotherapy-induced myocardial ischemic injury and preparation method | |
| CN104258032A (en) | Traditional Chinese medicine composition for treating stomach cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Na Inventor after: Fu Dexiang Inventor before: Fu Dexiang |
|
| CB03 | Change of inventor or designer information | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160622 |
|
| WW01 | Invention patent application withdrawn after publication |